SEC Filings
Gilead's Biktarvy Medicare Price Is Now Set, Effective January 1, 2028
The drugmaker's quarterly report replaces a hedged warning with a finished Medicare negotiation for its $4.06 billion-a-quarter HIV drug.
Gilead Sciences (GILD) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The drugmaker's quarterly report replaces a hedged warning with a finished Medicare negotiation for its $4.06 billion-a-quarter HIV drug.
Earnings
Kite's Cindy Perettie said there were no patient deaths, and that Gilead's FDA decision on anito-cel is due December 23.
Earnings
CEO Daniel O'Day says the government's price ignores Biktarvy's value, while the CFO still expects 2028 earnings per share to grow.
Deals
HIV sales rose 18% in the third quarter, yet $12.4 billion in acquired research charges widen the projected full-year loss per share.